



## Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS.

Regd. Office: 4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar-393002.

Administrative Office: 101, Shiv Shakti Industrial Estate, Andheri-Kurla Rd., Andheri (East), Mumbai -400059.

### UNAUDITED FINANCIAL RESULTS (PROVISIONAL) OF QUARTER ENDED 30TH SEPTEMBER, 2007

(Rs. in Lacs)

	Quarter Ended 30.09.2007 (Unaudited)	Quarter Ended 30.09.2006 (Unaudited)	6 Months Ended 30.09.2007 (Unaudited)	18 Months Ended 31.03.2007 (Audited)
1. Net Sales/Income from operations	3302.03	2366.17	5708.76	13427.79
2. Other Income	107.18	22.19	202.23	987.08
3. Total Expenditure				
(a) (Increase)/Decrease in Stock in Trade	18.09	(32.39)	(40.00)	(82.82)
(b) Consumption of Materials	1886.33	1415.03	3183.43	8955.58
(c) Staff Cost	170.70	118.91	335.49	847.77
(d) Other Expenditure (Incl. Excise Duty)	874.17	568.87	1568.41	3347.47
	2949.29	2070.42	5047.33	13068.00
4. Operational Profit / (Loss) before Interest, Depreciation and Taxation	459.92	317.94	863.66	1346.87
5. Interest & Finance Cost	170.76	192.45	360.17	874.88
6. Depreciation	46.81	40.52	86.16	213.19
7. Profit / (Loss) before Tax (4-5-6)	242.35	84.97	417.33	258.80
8. Bad Debts/Advances Written off	-	-	-	1,761.56
9. Loss on Investment	-	-	-	368.00
10. Earlier Year Taxes	-	-	-	(119.20)
Provision for Tax (FBT)	3.00	2.54	6.00	13.98
11. Net Profit / (Loss) (7-8-9-10)	239.35	82.43	411.33	(1765.54)
12. Paid-up Equity Share Capital (Face Value Rs.10/- per Share)	1648.50	1465.00	1648.50	1527.50
Paid up Pref. Share Capital (Face Value Rs. 100/- per Share)	108.57	108.57	108.57	108.57
13. Reserves excluding Revaluation Reserve				2,782.70
14. Earning Per Share on PBT (Rs.) (Basic & Diluted)	1.54	0.56	2.66	(12.53)
15. Aggregate of Non-promoter Share-holding Number of Shares	12,902,735	11,742,785	12,902,735	11,892,785
Percentage of Shareholding	78.27	80.16	78.27	77.86

Notes:

- The above results, were duly considered by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 31st October, 2007.
- The Company has one Single Segment "Pharmaceuticals".
- Net sales/Income from operations includes Processing Charges of Rs. 202.82 Lacs.
- The loss/gain on exchange fluctuation on GDR Funds for the current year will be provided at the end of the year.
- No depreciation has been provided in respect of revalued Assets for Building and Plant & Machinery during the quarter.
- 3 (three) complaints of Investors received during the quarter has been resolved.
- Previous period/quarter figures have been regrouped wherever necessary.
- Audit qualifications in respect of Audited Accounts for 2005-07 and management comments thereon are detailed below:
  - The deferment of R & D expenditure of Rs.1,61,14,667/- & GDR Issue expenses of Rs. 91,61,542/- which is not in compliance with Accounting Standard (AS-26). The Company has explained at note No. 15 to the accounts.
  - Regarding non-provision of arrears of ex-gratia at Rs.3,66,69,307/-, the matter presently is subjudice.

Place : Mumbai  
Dated : 31st October, 2007

For **LYKA LABS LIMITED**  
**(N. I. GANDHI)**  
Chairman & Managing Director

EPRESSMAN